Trends in Noninvasive and Invasive Mechanical Ventilation Among Medicare Beneficiaries at the End of Life
End-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to avoid invasive mechanical ventilation (IMV) among select patients who are hospitalized at the end of life. To examine the trends in NIV and IMV...
Uloženo v:
| Vydáno v: | JAMA internal medicine Ročník 181; číslo 1; s. 93 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.01.2021
|
| Témata: | |
| ISSN: | 2168-6114, 2168-6114 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | End-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to avoid invasive mechanical ventilation (IMV) among select patients who are hospitalized at the end of life.
To examine the trends in NIV and IMV use among decedents with a hospitalization in the last 30 days of life.
This population-based cohort study used a 20% random sample of Medicare fee-for-service beneficiaries who had an acute care hospitalization in the last 30 days of life and died between January 1, 2000, and December 31, 2017. Sociodemographic, diagnosis, and comorbidity data were obtained from Medicare claims data. Data analysis was performed from September 2019 to July 2020.
Use of NIV or IMV.
Validated International Classification of Diseases, Ninth Revision, Clinical Modification or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification procedure codes were reviewed to identify use of NIV, IMV, both NIV and IMV, or none. Four subcohorts of Medicare beneficiaries were identified using primary admitting diagnosis codes (chronic obstructive pulmonary disease [COPD], congested heart failure [CHF], cancer, and dementia). Measures of end-of-life care included in-hospital death (acute care setting), hospice enrollment at death, and hospice enrollment in the last 3 days of life. Random-effects logistic regression examined NIV and IMV use adjusted for sociodemographic characteristics, admitting diagnosis, and comorbidities.
A total of 2 470 435 Medicare beneficiaries (1 353 798 women [54.8%]; mean [SD] age, 82.2 [8.2] years) were hospitalized within 30 days of death. Compared with 2000, the adjusted odds ratio (AOR) for the increase in NIV use was 2.63 (95% CI, 2.46-2.82; % receipt: 0.8% vs 2.0%) for 2005 and 11.84 (95% CI, 11.11-12.61; % receipt: 0.8% vs 7.1%) for 2017. Compared with 2000, the AOR for the increase in IMV use was 1.04 (95% CI, 1.02-1.06; % receipt: 15.0% vs 15.2%) for 2005 and 1.63 (95% CI, 1.59-1.66; % receipt: 15.0% vs 18.2%) for 2017. In subanalyses comparing 2017 with 2000, similar trends found increased NIV among patients with CHF (% receipt: 1.4% vs 14.2%; AOR, 14.14 [95% CI, 11.77-16.98]) and COPD (% receipt: 2.7% vs 14.5%; AOR, 8.22 [95% CI, 6.42-10.52]), with reciprocal stabilization in IMV use among patients with CHF (% receipt: 11.1% vs 7.8%; AOR, 1.07 [95% CI, 0.95-1.19]) and COPD (% receipt: 17.4% vs 13.2%; AOR, 1.03 [95% CI, 0.88-1.21]). The AOR for increased NIV use was 10.82 (95% CI, 8.16-14.34; % receipt: 0.4% vs 3.5%) among decedents with cancer and 9.62 (95% CI, 7.61-12.15; % receipt: 0.6% vs 5.2%) among decedents with dementia. The AOR for increased IMV use was 1.40 (95% CI, 1.26-1.55; % receipt: 6.2% vs 7.6%) among decedents with cancer and 1.28 (95% CI, 1.17-1.41; % receipt: 5.7% vs 6.2%) among decedents with dementia. Among decedents with NIV vs IMV use, lower rates of in-hospital death (50.3% [95% CI, 49.3%-51.3%] vs 76.7% [95% CI, 75.9%-77.5%]) and hospice enrollment in the last 3 days of life (57.7% [95% CI, 56.2%-59.3%] vs 63.0% [95% CI, 60.9%-65.1%]) were observed along with higher rates of hospice enrollment (41.3% [95% CI, 40.4%-42.3%] vs 20.0% [95% CI, 19.2%-20.7%]).
This study found that the use of NIV rapidly increased from 2000 through 2017 among Medicare beneficiaries at the end of life, especially among persons with cancer and dementia. The findings suggest that trials to evaluate the outcomes of NIV are warranted to inform discussions about the goals of this therapy between clinicians and patients and their health care proxies. |
|---|---|
| AbstractList | End-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to avoid invasive mechanical ventilation (IMV) among select patients who are hospitalized at the end of life.
To examine the trends in NIV and IMV use among decedents with a hospitalization in the last 30 days of life.
This population-based cohort study used a 20% random sample of Medicare fee-for-service beneficiaries who had an acute care hospitalization in the last 30 days of life and died between January 1, 2000, and December 31, 2017. Sociodemographic, diagnosis, and comorbidity data were obtained from Medicare claims data. Data analysis was performed from September 2019 to July 2020.
Use of NIV or IMV.
Validated International Classification of Diseases, Ninth Revision, Clinical Modification or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification procedure codes were reviewed to identify use of NIV, IMV, both NIV and IMV, or none. Four subcohorts of Medicare beneficiaries were identified using primary admitting diagnosis codes (chronic obstructive pulmonary disease [COPD], congested heart failure [CHF], cancer, and dementia). Measures of end-of-life care included in-hospital death (acute care setting), hospice enrollment at death, and hospice enrollment in the last 3 days of life. Random-effects logistic regression examined NIV and IMV use adjusted for sociodemographic characteristics, admitting diagnosis, and comorbidities.
A total of 2 470 435 Medicare beneficiaries (1 353 798 women [54.8%]; mean [SD] age, 82.2 [8.2] years) were hospitalized within 30 days of death. Compared with 2000, the adjusted odds ratio (AOR) for the increase in NIV use was 2.63 (95% CI, 2.46-2.82; % receipt: 0.8% vs 2.0%) for 2005 and 11.84 (95% CI, 11.11-12.61; % receipt: 0.8% vs 7.1%) for 2017. Compared with 2000, the AOR for the increase in IMV use was 1.04 (95% CI, 1.02-1.06; % receipt: 15.0% vs 15.2%) for 2005 and 1.63 (95% CI, 1.59-1.66; % receipt: 15.0% vs 18.2%) for 2017. In subanalyses comparing 2017 with 2000, similar trends found increased NIV among patients with CHF (% receipt: 1.4% vs 14.2%; AOR, 14.14 [95% CI, 11.77-16.98]) and COPD (% receipt: 2.7% vs 14.5%; AOR, 8.22 [95% CI, 6.42-10.52]), with reciprocal stabilization in IMV use among patients with CHF (% receipt: 11.1% vs 7.8%; AOR, 1.07 [95% CI, 0.95-1.19]) and COPD (% receipt: 17.4% vs 13.2%; AOR, 1.03 [95% CI, 0.88-1.21]). The AOR for increased NIV use was 10.82 (95% CI, 8.16-14.34; % receipt: 0.4% vs 3.5%) among decedents with cancer and 9.62 (95% CI, 7.61-12.15; % receipt: 0.6% vs 5.2%) among decedents with dementia. The AOR for increased IMV use was 1.40 (95% CI, 1.26-1.55; % receipt: 6.2% vs 7.6%) among decedents with cancer and 1.28 (95% CI, 1.17-1.41; % receipt: 5.7% vs 6.2%) among decedents with dementia. Among decedents with NIV vs IMV use, lower rates of in-hospital death (50.3% [95% CI, 49.3%-51.3%] vs 76.7% [95% CI, 75.9%-77.5%]) and hospice enrollment in the last 3 days of life (57.7% [95% CI, 56.2%-59.3%] vs 63.0% [95% CI, 60.9%-65.1%]) were observed along with higher rates of hospice enrollment (41.3% [95% CI, 40.4%-42.3%] vs 20.0% [95% CI, 19.2%-20.7%]).
This study found that the use of NIV rapidly increased from 2000 through 2017 among Medicare beneficiaries at the end of life, especially among persons with cancer and dementia. The findings suggest that trials to evaluate the outcomes of NIV are warranted to inform discussions about the goals of this therapy between clinicians and patients and their health care proxies. End-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to avoid invasive mechanical ventilation (IMV) among select patients who are hospitalized at the end of life.ImportanceEnd-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to avoid invasive mechanical ventilation (IMV) among select patients who are hospitalized at the end of life.To examine the trends in NIV and IMV use among decedents with a hospitalization in the last 30 days of life.ObjectiveTo examine the trends in NIV and IMV use among decedents with a hospitalization in the last 30 days of life.This population-based cohort study used a 20% random sample of Medicare fee-for-service beneficiaries who had an acute care hospitalization in the last 30 days of life and died between January 1, 2000, and December 31, 2017. Sociodemographic, diagnosis, and comorbidity data were obtained from Medicare claims data. Data analysis was performed from September 2019 to July 2020.Design, Setting, and ParticipantsThis population-based cohort study used a 20% random sample of Medicare fee-for-service beneficiaries who had an acute care hospitalization in the last 30 days of life and died between January 1, 2000, and December 31, 2017. Sociodemographic, diagnosis, and comorbidity data were obtained from Medicare claims data. Data analysis was performed from September 2019 to July 2020.Use of NIV or IMV.ExposuresUse of NIV or IMV.Validated International Classification of Diseases, Ninth Revision, Clinical Modification or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification procedure codes were reviewed to identify use of NIV, IMV, both NIV and IMV, or none. Four subcohorts of Medicare beneficiaries were identified using primary admitting diagnosis codes (chronic obstructive pulmonary disease [COPD], congested heart failure [CHF], cancer, and dementia). Measures of end-of-life care included in-hospital death (acute care setting), hospice enrollment at death, and hospice enrollment in the last 3 days of life. Random-effects logistic regression examined NIV and IMV use adjusted for sociodemographic characteristics, admitting diagnosis, and comorbidities.Main Outcomes and MeasuresValidated International Classification of Diseases, Ninth Revision, Clinical Modification or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification procedure codes were reviewed to identify use of NIV, IMV, both NIV and IMV, or none. Four subcohorts of Medicare beneficiaries were identified using primary admitting diagnosis codes (chronic obstructive pulmonary disease [COPD], congested heart failure [CHF], cancer, and dementia). Measures of end-of-life care included in-hospital death (acute care setting), hospice enrollment at death, and hospice enrollment in the last 3 days of life. Random-effects logistic regression examined NIV and IMV use adjusted for sociodemographic characteristics, admitting diagnosis, and comorbidities.A total of 2 470 435 Medicare beneficiaries (1 353 798 women [54.8%]; mean [SD] age, 82.2 [8.2] years) were hospitalized within 30 days of death. Compared with 2000, the adjusted odds ratio (AOR) for the increase in NIV use was 2.63 (95% CI, 2.46-2.82; % receipt: 0.8% vs 2.0%) for 2005 and 11.84 (95% CI, 11.11-12.61; % receipt: 0.8% vs 7.1%) for 2017. Compared with 2000, the AOR for the increase in IMV use was 1.04 (95% CI, 1.02-1.06; % receipt: 15.0% vs 15.2%) for 2005 and 1.63 (95% CI, 1.59-1.66; % receipt: 15.0% vs 18.2%) for 2017. In subanalyses comparing 2017 with 2000, similar trends found increased NIV among patients with CHF (% receipt: 1.4% vs 14.2%; AOR, 14.14 [95% CI, 11.77-16.98]) and COPD (% receipt: 2.7% vs 14.5%; AOR, 8.22 [95% CI, 6.42-10.52]), with reciprocal stabilization in IMV use among patients with CHF (% receipt: 11.1% vs 7.8%; AOR, 1.07 [95% CI, 0.95-1.19]) and COPD (% receipt: 17.4% vs 13.2%; AOR, 1.03 [95% CI, 0.88-1.21]). The AOR for increased NIV use was 10.82 (95% CI, 8.16-14.34; % receipt: 0.4% vs 3.5%) among decedents with cancer and 9.62 (95% CI, 7.61-12.15; % receipt: 0.6% vs 5.2%) among decedents with dementia. The AOR for increased IMV use was 1.40 (95% CI, 1.26-1.55; % receipt: 6.2% vs 7.6%) among decedents with cancer and 1.28 (95% CI, 1.17-1.41; % receipt: 5.7% vs 6.2%) among decedents with dementia. Among decedents with NIV vs IMV use, lower rates of in-hospital death (50.3% [95% CI, 49.3%-51.3%] vs 76.7% [95% CI, 75.9%-77.5%]) and hospice enrollment in the last 3 days of life (57.7% [95% CI, 56.2%-59.3%] vs 63.0% [95% CI, 60.9%-65.1%]) were observed along with higher rates of hospice enrollment (41.3% [95% CI, 40.4%-42.3%] vs 20.0% [95% CI, 19.2%-20.7%]).ResultsA total of 2 470 435 Medicare beneficiaries (1 353 798 women [54.8%]; mean [SD] age, 82.2 [8.2] years) were hospitalized within 30 days of death. Compared with 2000, the adjusted odds ratio (AOR) for the increase in NIV use was 2.63 (95% CI, 2.46-2.82; % receipt: 0.8% vs 2.0%) for 2005 and 11.84 (95% CI, 11.11-12.61; % receipt: 0.8% vs 7.1%) for 2017. Compared with 2000, the AOR for the increase in IMV use was 1.04 (95% CI, 1.02-1.06; % receipt: 15.0% vs 15.2%) for 2005 and 1.63 (95% CI, 1.59-1.66; % receipt: 15.0% vs 18.2%) for 2017. In subanalyses comparing 2017 with 2000, similar trends found increased NIV among patients with CHF (% receipt: 1.4% vs 14.2%; AOR, 14.14 [95% CI, 11.77-16.98]) and COPD (% receipt: 2.7% vs 14.5%; AOR, 8.22 [95% CI, 6.42-10.52]), with reciprocal stabilization in IMV use among patients with CHF (% receipt: 11.1% vs 7.8%; AOR, 1.07 [95% CI, 0.95-1.19]) and COPD (% receipt: 17.4% vs 13.2%; AOR, 1.03 [95% CI, 0.88-1.21]). The AOR for increased NIV use was 10.82 (95% CI, 8.16-14.34; % receipt: 0.4% vs 3.5%) among decedents with cancer and 9.62 (95% CI, 7.61-12.15; % receipt: 0.6% vs 5.2%) among decedents with dementia. The AOR for increased IMV use was 1.40 (95% CI, 1.26-1.55; % receipt: 6.2% vs 7.6%) among decedents with cancer and 1.28 (95% CI, 1.17-1.41; % receipt: 5.7% vs 6.2%) among decedents with dementia. Among decedents with NIV vs IMV use, lower rates of in-hospital death (50.3% [95% CI, 49.3%-51.3%] vs 76.7% [95% CI, 75.9%-77.5%]) and hospice enrollment in the last 3 days of life (57.7% [95% CI, 56.2%-59.3%] vs 63.0% [95% CI, 60.9%-65.1%]) were observed along with higher rates of hospice enrollment (41.3% [95% CI, 40.4%-42.3%] vs 20.0% [95% CI, 19.2%-20.7%]).This study found that the use of NIV rapidly increased from 2000 through 2017 among Medicare beneficiaries at the end of life, especially among persons with cancer and dementia. The findings suggest that trials to evaluate the outcomes of NIV are warranted to inform discussions about the goals of this therapy between clinicians and patients and their health care proxies.Conclusions and RelevanceThis study found that the use of NIV rapidly increased from 2000 through 2017 among Medicare beneficiaries at the end of life, especially among persons with cancer and dementia. The findings suggest that trials to evaluate the outcomes of NIV are warranted to inform discussions about the goals of this therapy between clinicians and patients and their health care proxies. |
| Author | Sullivan, Donald R Bunker, Jennifer Kim, Hyosin Gozalo, Pedro L Teno, Joan M |
| Author_xml | – sequence: 1 givenname: Donald R surname: Sullivan fullname: Sullivan, Donald R organization: Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Healthcare System, Portland, Oregon – sequence: 2 givenname: Hyosin surname: Kim fullname: Kim, Hyosin organization: Division of General Internal Medicine and Geriatrics, School of Medicine, Oregon Health and Science University, Portland – sequence: 3 givenname: Pedro L surname: Gozalo fullname: Gozalo, Pedro L organization: Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island – sequence: 4 givenname: Jennifer surname: Bunker fullname: Bunker, Jennifer organization: Division of General Internal Medicine and Geriatrics, School of Medicine, Oregon Health and Science University, Portland – sequence: 5 givenname: Joan M surname: Teno fullname: Teno, Joan M organization: Division of General Internal Medicine and Geriatrics, School of Medicine, Oregon Health and Science University, Portland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33074320$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUE1PwkAQ3RiMIPIXdI9eivvVbXtEgkqCekGvzdDOypJ2it1C4r-3Rkmcy5uX9-Yl8y7ZgBpCxm6kmEoh5N0OavDUYUs1llMllJjG1ogzNlLSppGV0gz-7UM2CWEn-kmFMFpfsKHWIjFaiRHz6xapDNwTf2nI0xGCPyIHKvnyRJ6x2AL5Air-jtT5CjrfEJ_VDX30YtkrLfJ7JHS-8NB6DBw63m2RL_qcxvGVd3jFzh1UASd_OGZvD4v1_ClavT4u57NVBMaaLrIGs0QkDktpTGydsi52mUoQNi7eKNE_CtqgyJRGG7s0y0qTGlSukFlaWK3G7PY3d982nwcMXV77UGBVAWFzCLkyseqvVfxjvf6zHjZ9lfm-9TW0X_mpHvUNK_lsug |
| CitedBy_id | crossref_primary_10_1001_jamanetworkopen_2024_27610 crossref_primary_10_1111_jgs_18196 crossref_primary_10_3390_jcm14145033 crossref_primary_10_1111_jgs_17680 crossref_primary_10_1097_CCM_0000000000005827 crossref_primary_10_1016_j_pecinn_2023_100241 crossref_primary_10_1111_jgs_19100 crossref_primary_10_1093_geront_gnae131 crossref_primary_10_1186_s12904_024_01365_y crossref_primary_10_1111_jgs_17564 crossref_primary_10_1371_journal_pone_0281447 crossref_primary_10_3390_diseases11040151 crossref_primary_10_1111_jgs_19119 crossref_primary_10_1016_j_jpainsymman_2022_02_011 crossref_primary_10_1016_j_jpainsymman_2024_04_021 crossref_primary_10_1001_jamanetworkopen_2024_20388 crossref_primary_10_1007_s11606_021_06794_6 crossref_primary_10_1007_s00520_022_07007_4 crossref_primary_10_1513_AnnalsATS_202308_694OC crossref_primary_10_1542_hpeds_2024_007999 crossref_primary_10_1001_jamainternmed_2023_2371 crossref_primary_10_1007_s00063_023_01061_4 crossref_primary_10_1016_j_ajem_2025_02_015 crossref_primary_10_1136_bmjopen_2024_089835 crossref_primary_10_7759_cureus_33143 crossref_primary_10_1016_j_rmed_2023_107223 crossref_primary_10_1093_geront_gnac160 crossref_primary_10_1136_bmjopen_2020_048344 crossref_primary_10_1016_j_jsmc_2024_04_010 crossref_primary_10_1007_s00063_023_01016_9 crossref_primary_10_1186_s40463_023_00662_5 crossref_primary_10_1177_10499091221134030 crossref_primary_10_1097_CCE_0000000000000574 crossref_primary_10_1177_17474930251338611 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamainternmed.2020.5640 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6114 |
| ExternalDocumentID | 33074320 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: NIA NIH HHS grantid: R56 AG063748 |
| GroupedDBID | 0R~ 4.4 53G AAGZG AARDX AAWTL ABBLC ABJNI ABPMR ACDNT ACGFS ADBBV AENEX AFCHL AGFXO AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EMOBN EX3 H13 HF~ NPM OB2 OBH OCB OGEVE OHH OVD PQQKQ RAJ SV3 TEORI WH7 WOW YCJ YYP 7X8 |
| ID | FETCH-LOGICAL-a464t-64e9707fed14456f26f5f927eabf5b20640a34e0923e65f899d484e2fc198c632 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 34 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000587482100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2168-6114 |
| IngestDate | Wed Oct 01 14:14:06 EDT 2025 Thu Jan 02 22:31:13 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a464t-64e9707fed14456f26f5f927eabf5b20640a34e0923e65f899d484e2fc198c632 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2771820/jamainternal_sullivan_2020_oi_200081_1609365335.89341.pdf |
| PMID | 33074320 |
| PQID | 2452092253 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2452092253 pubmed_primary_33074320 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA internal medicine |
| PublicationTitleAlternate | JAMA Intern Med |
| PublicationYear | 2021 |
| References | 33074308 - JAMA Intern Med. 2021 Jan 1;181(1):102-103. doi: 10.1001/jamainternmed.2020.5648 |
| References_xml | – reference: 33074308 - JAMA Intern Med. 2021 Jan 1;181(1):102-103. doi: 10.1001/jamainternmed.2020.5648 |
| SSID | ssj0000800433 |
| Score | 2.4999495 |
| Snippet | End-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 93 |
| SubjectTerms | Aged Aged, 80 and over Cohort Studies Female Humans Male Medicare - statistics & numerical data Noninvasive Ventilation - trends Terminal Care - trends United States |
| Title | Trends in Noninvasive and Invasive Mechanical Ventilation Among Medicare Beneficiaries at the End of Life |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33074320 https://www.proquest.com/docview/2452092253 |
| Volume | 181 |
| WOSCitedRecordID | wos000587482100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDI6AIcSF92O8FCSuhS5N0vSEBtoEEqt2ALRblbWO1Es7trHfj90HnJCQuFTqoa_Ytf3ZX2zGbiJtenrqUAIGtCcNYlZj_cxDZ47eWhtwvquGTYRxbCaTaNwk3BYNrbK1iZWhzsqUcuR3VCH0I9S-4H724dHUKKquNiM01lknwFCGtDqcmO8cC0VDspomL_CxiJJ6sqV4NY2H8irthn4HkaLwb5WW_u-hZuVyhrv_fdk9ttMEm7xfa8c-W4PigG2NmnL6IctrRizPCx5TWnZliczObZHx5_ZkBLQ3mETJ34lZVHPneJ-GFPG6zDMH_oAms-pFQcib2yXHuJIP8D6l4y-5gyP2Nhy8Pj55zewFz0otl56WEIV-6CBDxKW0E9opF4kQ7NSpqaD6nw0k4EcGoJVD1JZJI0G4tBeZVAfimG0UZQGnjFva-4peL1MpgvFU2ghSYSOrlAapjeyy63YRE9RtKljYAsrPRfKzjF12UksimdVNOJIgoOBH-Gd_uPqcbQuiolSZkwvWcfhnwyXbTFfLfDG_qpQGj_F49AWGkcrR |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+Noninvasive+and+Invasive+Mechanical+Ventilation+Among+Medicare+Beneficiaries+at+the+End+of+Life&rft.jtitle=JAMA+internal+medicine&rft.au=Sullivan%2C+Donald+R&rft.au=Kim%2C+Hyosin&rft.au=Gozalo%2C+Pedro+L&rft.au=Bunker%2C+Jennifer&rft.date=2021-01-01&rft.eissn=2168-6114&rft.volume=181&rft.issue=1&rft.spage=93&rft_id=info:doi/10.1001%2Fjamainternmed.2020.5640&rft_id=info%3Apmid%2F33074320&rft_id=info%3Apmid%2F33074320&rft.externalDocID=33074320 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6114&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6114&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6114&client=summon |